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Treatment of tuberculosis, like other infectious
diseases, is increasingly hindered by the emergence
of drug resistance. Drug discovery efforts would be
facilitated by facile screening tools that incorporate
the complexities of human disease. Mycobacterium
marinum-infected zebrafish larvae recapitulate key
aspects of tuberculosis pathogenesis and drug treat-
ment. Here, we develop amodel for rapid in vivo drug
screening using fluorescence-based methods for
serial quantitative assessment of drug efficacy and
toxicity. We provide proof-of-concept that both
traditional bacterial-targeting antitubercular drugs
and newly identified host-targeting drugs would be
discovered through the use of this model. We
demonstrate the model’s utility for the identification
of synergistic combinations of antibacterial drugs
and demonstrate synergy between bacterial- and
host-targeting compounds. Thus, the platform can
be used to identify new antibacterial agents and
entirely new classes of drugs that thwart infection
by targeting host pathways. The methods developed
here should be widely applicable to small-molecule
screens for other infectious and noninfectious
diseases.INTRODUCTION
The zebrafish has emerged as a favorite organism for wide-
ranging studies of development and disease owing to its genetic
tractability and facile husbandry (Mione and Trede, 2010; Trede
et al., 2004). Moreover, zebrafish larvae are an attractive tool for
drug screens as their small size (2 mm) and optical transpar-
ency allow for husbandry in multiwell plates and evaluation by
fluorescence detection techniques, respectively (Cao et al.,
2009; Milan et al., 2009; Ou et al., 2012; Peterson and Fishman,
2004; Stern et al., 2005; Tan and Zon, 2011; Zon and Peterson,
2005). Such screens have been used to discover drugs that
modulate developmental and disease pathways shared withhumans (Cusick et al., 2012; Milan et al., 2003; Peterson and
Fishman, 2004; Rudner et al., 2011).
Zebrafish possess a complex immune system akin to that of
humans (Traver et al., 2003; Trede et al., 2004) and have been
instrumental in identifying pathways that mediate disease path-
ogenesis (Etchin et al., 2011; Martin et al., 2011; Mione and
Trede, 2010). The zebrafish larva infected with fluorescently
labeled Mycobacterium marinum (Mm) has proved an excellent
model for the in vivo dissection of tuberculosis (TB) pathogen-
esis. Use of this model enabled the identification and mecha-
nistic dissection of host and bacterial determinants, thus yielding
new insights into TB (Davis and Ramakrishnan, 2009; Tobin and
Ramakrishnan, 2008; Tobin et al., 2010; Volkman et al., 2010). In
particular, discoveries about the roles of macrophages, granu-
lomas, and inflammation have suggested completely new
approaches to treating this ancient disease (Clay et al., 2007;
Davis and Ramakrishnan, 2009; Tobin et al., 2010, 2012; Volk-
man et al., 2010).
Existing TB therapies are increasingly limited by the emer-
gence of drug-resistant diseases, including Mycobacterium
tuberculosis (Mtb) strains that are resistant to all known antitu-
bercular drugs (Udwadia et al., 2012; Zignol et al., 2012). There
has been a resurgence of interest in antimicrobial drug dis-
covery, and modern genomic and chemical synthetic methods
are now being used to search for new classes of drugs. While
a few compounds have emerged for select organisms, these
approaches have been largely unsuccessful in identifying new
antibiotics (Payne et al., 2007; Pethe et al., 2010). While the
causes for this failure are many, two main problems are as
follows: (1) Compounds identified by in vitro, target-based
screens may not inhibit bacterial growth; and (2) compounds
identified in ‘‘whole-cell’’ screens using bacteria in axenic culture
may not be active against bacteria in vivo. Thus, a major bottle-
neck in drug discovery is the lack of a facile yet relevantmodel for
drug screening. In vivo screening is particularly important
because TB is a complex disease in which the bacteria sense
and exploit host defenses (Volkman et al., 2004). The mouse
model of TB has been widely used for antitubercular drug testing
and has predicted the behavior of many drugs in humans (Dor-
man et al., 2009;Mitchison andChang, 2009), including the pres-
ence of tolerance. However, its use is expensive, time
consuming, and laborious: The discovery of the antitubercular
activity of isoniazid (INH) involved the use of 50,000 mice toCell Reports 2, 175–184, July 26, 2012 ª2012 The Authors 175
screen 5,000 compounds and only assessed efficacy—then,
toxicity studies required additional mice (Tweedy and Lesney,
2000). More recently, high content screening (HCS) platforms
have been applied to intracellular pathogens such as Salmonella
(Kuijl et al., 2007) and Mtb (Christophe et al., 2009), in which
compound screening is performed on infected macrophages in
multiwell format, allowing the assessment of drug activity
against intracellular bacteria. Given the high attrition of lead
compounds due to host toxicity and lack of efficacy in vivo,
a screening platform that replicates the complexities of in vivo
treatment, yet is amenable to high-throughput methodologies,
is highly desirable.
Recently, we found that first-line antitubercular drugs were
active against Mm infection in zebrafish larvae, recapitulating
important clinical features of human disease including early
bactericidal activity (EBA), the localized responsiveness of indi-
vidual granulomas, drug synergies, and drug tolerance (Adams
et al., 2011). Here, we present the Mm-zebrafish larval model
as a platform for in vivo antitubercular drug discovery. We
describe high-throughput methodologies for larval husbandry
and imaging, as well as a fluorimetry platform that allows rapid,
serial quantitation of both drug efficacy and toxicity. We demon-
strate the utility of the platform for compound screening of both
bacterial- and host-targeting drugs, as well as for synergistic
drug combinations. The high-throughput methods we have
developed should have broad utility for compound screening in
the zebrafish.
RESULTS
High-Throughput Husbandry and Cryoanesthesia
of Zebrafish Larvae
A versatile compound-screening platform would ideally allow
maintenance and serial imaging of larvae in situ, require only
a single application of compound, and permit observation over
the course of several days. In the Mm-larval model, infected
larvae are maintained in petri dishes with regular water changes,
and bacterial burdens are enumerated by imaging and quantifi-
cation by fluorescent pixel count (FPC) (Adams et al., 2011).
Because larval motility interferes with imaging, they must be
transferred into tricaine-containing medium, then to glass slides
for imaging, and finally returned to tricaine-free maintenance
conditions (Adams et al., 2011; Cosma et al., 2006a; Tobin
et al., 2010; Volkman et al., 2010). To remove these barriers to
high-throughput implementation, we first established that 3
day postfertilization (dpf) larvae could be maintained in optical-
bottom 96-well plates without water changes or feeding for
10 days with no mortality (Figure S1A; data not shown). Next,
we found that cryoanesthesia of larvae was an effective and
reversible immobilization technique. Incubation of the 96-well
plates on ice for 10 min prevented larval movement for an addi-
tional 10 min at room temperature (data not shown), without
affecting larval viability (Figure S1A) or altering the course of
Mm infection as judged by overall bacterial burdens and the
distribution of infection (Figures S1B and S1C). Finally, we auto-
mated fluorescence microscopy, image collection, and analysis
(see Experimental Procedures; Documents S1 and S2), allowing
an entire plate to be imaged in only 4 min. In summary, 96-well176 Cell Reports 2, 175–184, July 26, 2012 ª2012 The Authorshusbandry and automated imaging of cryoanesthetized larvae
allows for rapid, serial, and high-throughput data collection.
Automated Plate Fluorimetry for Rapid Dual-Assay Drug
Screening
Because of the relatively low cost and wider availability of micro-
plate fluorimeters as compared to automated fluorescence
microscopes and specialized image analysis software, we addi-
tionally developed fluorimetric assays for in situ fluorescence
monitoring of larvae in 96-well plates. Preliminary analyses of
uninfected larvae revealed more background fluorescence at
shorter wavelengths, consistent with the long-standing observa-
tion of less biological autofluorescence at longer wavelengths in
a variety of biological tissues. Therefore, we assessed Mm
strains constitutively expressing the widely used fluors GFPmut3
(‘‘green’’) and dsRed2 (‘‘red’’), as well as the newly available
tdKatushka2 (Shcherbo et al., 2009), which fluoresces in the
far-red range (Table S1). Of the three fluors tested, tdKatushka2
provided the brightest signal, approximately 3-fold that of
GFPmut3 and twice that of dsRed2 (Figure 1A). Additionally,
fluorimetry was a reliable indicator of relative bacterial number,
showing a linear relationship between fluorescence intensity
and the number of bacterial cells in suspension (Figure 1B). We
next assessed the background noise resulting from autofluores-
cence of uninfected larvae in all three channels. As expected, the
degree of autofluorescence was inversely correlated with wave-
length (Figure 1C). Finally, we examined larvae with varying Mm
infection burdens by automated plate fluorimetry (APF) and
compared the results with our established method, FPC (Fig-
ure 1D). The two methods correlated well for all three fluors,
with the best correlation being seen with tdKatushka2, consis-
tent with its superior signal to noise ratio. It is important to note
that this assessment did not require anesthesia of the larvae,
further increasing its throughput.
Tracking larval survival during a screen can provide informa-
tion regarding both compound efficacy and toxicity. While char-
acterizing larval autofluorescence, we observed that green, but
not red, autofluorescence was much higher in dead larvae, as
compared to live ones (Figure 1E). To examine the timing and
predictive value of green autofluorescence for the automated
assessment of survival, we monitored larvae with varying levels
of far-red Mm infection daily for 13 days. Viability was scored
by the standardmethod of assessing the presence of a heartbeat
by stereomicroscopy (‘‘cardiac assessment’’) and by green
autofluorescence by APF (Figure 1F). The mean fluorescence
of dead larvae was three times higher than that of live larvae,
and receiver operator characteristic (ROC) analysis showed
that autofluorescence is highly predictive of viability (area under
the curve [AUC] = 0.99) (Figure 1G). Using a cutoff of 50% of the
mean fluorescence of dead larvae, only four false-positives and
five false-negatives occurred out of a total of 520 APF measure-
ments, for an error rate of 1.7%. Moreover, even these false-
negatives represented measurements taken in the window
between cardiac arrest and the ensuing increase in autofluores-
cence that results from tissue decay: when these five dead
larvae were reexamined 24 hr later, their autofluorescence had
increased, moving above the cutoff (Figure S2A). We confirmed
that this method can also be used in the presence of compounds
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Figure 1. Automated Plate Fluorimetry
(A and B) Fluorescence of bacteria expressing GFPmut3 (green), DsRed2 (red), or tdKatushka2 (far-red) was measured by APF. (A) Comparison of mean
fluorescence per 5 3 104 bacteria, n = 3. Error bars indicate SEM. (B) Linear relationship between number of bacteria and RFUs.
(C) Mean autofluorescence of live uninfected 7-dpf larvae was measured at wavelengths used for detection of the three fluors (n = 10). Error bars indicate SEM.
(D) Larvae were infected with varying doses of fluorescent Mm, and bacterial burdens were quantified by FPC and APF.
(E) Autofluorescence of individual uninfected larvae was measured at wavelengths used for detection of green- and red-fluorescent Mm from 4 to 12 dpf. Larvae
were also assessed daily for viability by cardiac assessment; alive (B), dead (d).
(F andG) Forty larvaewith varying levels of infectionwere housed in 96-well plates beginning at 2 dpf andweremonitored daily for green autofluorescence via APF
and survival state via cardiac assessment for 13 days, for a total of 520 APF measurements. (F) Graph shows larval autofluorescence, stratified by viability. Line
represents 3,000 RFUs, or 50% of the mean fluorescence of dead larvae. (G) ROC curve showing accuracy of green autofluorescence as predictor of viability.
See also Figures S1 and S2 and Table S1.like rifampicin (RIF) that absorb light and thus partially reduce au-
tofluorescencemeasurements in the green channel (Figures S2B
andS2C). In summary, green autofluorescence provides a versa-
tile, rapid, and automated readout to distinguish live from dead
larvae.
Because of its superior signal-to-noise ratio and compatibility
with the autofluorescence-based live/dead assay, we chose
tdKatushka2-expressing Mm for further experiments. However,
we note that the other fluors can also be used reliably, for
example, in assays evaluating drug effects on green or red fluo-
rescent markers in transgenic fish.
APF Reliably Detects Antitubercular Drug Efficacy
We previously showed that first-line antitubercular drugs are
active against larval Mm infection and recapitulate the efficacy
and tolerance profiles observed during human treatment
(Adams et al., 2011). To validate the 96-well APF format for anti-
tubercular compound screening, we first examined whether the
activities of known drugs could be detected using 400 mM drug
per well. This represents the equivalent of 100 nmol, an amount
that is feasible for one-time use in a screen. Larvae 1 day post-infection (dpi) with far-red fluorescent Mm were maintained
in 96-well plates in the presence and absence of the drugs
INH, RIF, ethambutol (EMB), and moxifloxacin (MOX) and were
monitored daily for viability and bacterial burdens. Larval viability
was scored by both cardiac assessment and green-channel
APF. Survival of treated larvae was significantly different from
the untreated controls, and the median times to death agreed
closely by the two methods (Figures 2A and 2B; Table S2).
Simultaneous daily assessment of the larvae by far-red APF
revealed that drug treatment also prevented the bacterial ex-
pansion that occurs in untreated animals (Figure 2C) and was
as sensitive as FPC in detecting the differences between treated
and untreated larvae (Figures 2D and 2E). ROC analysis of the
pooled APF data from treated versus untreated larvae shows
that the platform possesses strong predictive value for the
detection of antibiotic efficacy (AUC = 1; data not shown). For
example, using 20% of the mean untreated fluorescence as
a cutoff for drug efficacy would yield 32/32 true-positives and
0 false-positives. A screen in which 50% of the mean fluores-
cence of untreated larvae is used as the threshold would yield
32/32 true-positives and 3/8 false-positives.Cell Reports 2, 175–184, July 26, 2012 ª2012 The Authors 177
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Figure 2. Automated In Vivo Assessment of Antimycobacterial Drug Efficacy by APF
Larvae 1 dpi with 300 far-red fluorescent Mmwere placed in wells of 96-well plates (one larva per well) containing no antibiotic (UNT), EMB, INH, MOX, or RIF (all
at 400 mM). Uninfected (UN) larvae were also included and were not exposed to antibiotic; N = 8.
(A and B) Larval survival during the 12-day treatment period was determined using (A) APF of green-autofluorescence or (B) cardiac assessment of each larva by
stereomicroscopy. Each drug-treated group survived significantly longer than the UNT group as determined by individual log-rank tests (p values ranged
from <0.0001 to 0.0002).
(C) Bacterial burdens were measured daily by far-red APF. Mean RFU with SEM are shown.
(D and E) Fluorescence of individual untreated and treated larvae, from (C), at 5 dpt asmeasured (D) by APF and (E) by FPC. Bars represent geometric means, and
dotted line represents 20% of the mean untreated RFU.
See also Figures S3 and S4 and Table S2.Finally, we considered the possibility that tuberculous granu-
lomas, which form at 3 dpi in this model, could potentially impact
drug efficacy by altering bacterial physiology or limiting drug
access to sites of infection. Therefore, we asked whether APF
could be used for drug screening after granulomas had formed
and found that it could. AFP revealed that treatment initiated
3 dpi was similarly effective at improving larval survival (Figures
S3A and S3B) and reducing bacterial burdens (Figures S3C
and S3D) as it was when larvae were treated 1 dpi. ROC analysis
confirms that the platform remained highly predictive for drug
efficacy, even in the context of granulomatous infection
(AUC = 0.87, p = 0.016; Figure S3E).
In summary, the simultaneous assessment of host survival and
bacterial burdens allows for the identification of traditional anti-
microbial drugs as well as those that could potentially modify
host outcome without changing bacterial burdens. Finally,
a parallel screen for host toxicity is inherently built into the plat-
form, providing information on an additional critical parameter
in drug development.
APF Can Identify Synergistic Antibacterial Drug
Combinations
In the context of antimicrobial therapy, synergy is generally
defined as a response achieved by a drug combination that is178 Cell Reports 2, 175–184, July 26, 2012 ª2012 The Authorssuperior to that seen with the individual antibiotics therein (Pratt
and Fekety, 1986). For human TB therapy, drug synergisms have
been central in shortening time to sterilization and treatment
length, as exemplified by the addition of RIF to INH-containing
regimens (Donald and McIlleron, 2009). This synergistic effect
was apparent early; within days of treatment, a further reduction
in sputumbacterial counts was observedwith the drug combina-
tion compared to INH alone (Jindani et al., 2003). In the larval
model, the addition of RIF to INH similarly revealed a further
reduction in bacterial burdens by FPC, suggesting the utility of
the zebrafish to detect drug synergies (Adams et al., 2011). We
confirmed that APF could also detect the INH-RIF synergy
(Figure 3A).
We next predicted the existence of a possible synergy based
on a phenotype associated with a known mycobacterial muta-
tion. KasB is an acyl carrier protein involved in mycolic acid
biosynthesis, and kasB mutations in both Mtb and Mm render
the bacteria hypersusceptible to RIF in culture, presumably by
increasing cell wall permeability (Bhatt et al., 2007; Gao et al.,
2003). The Mm DkasB mutant was also hypersusceptible to
RIF in the context of zebrafish infection (Figure 3B). Next, we
examined whether thiolactomycin (TLM), an antibiotic that
targets KasB (Kremer et al., 2000), would synergize with RIF
in vivo. We tested a range of TLM concentrations with and
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Figure 3. Synergistic Drug Interactions in
the Zebrafish Larval Infection Model
(A) Larvae 1 dpi with 300 far-red fluorescent Mm
were treated with RIF (50 mM), INH (100 mM), or
both. Bacterial burdens were measured by APF at
5 dpt. Statistical analysis performed via ANOVA on
log10-transformed data, with Bonferroni’s post
hoc testing for individual comparisons. ***p <
0.001.
(B) Larvae 1 dpi with 100–200 wild-type (WT) or
500–1000 DkasB Mm-expressing GFPmut3
were treated with 290 mM RIF for 4 days before
quantification of bacterial burden by FPC. The
reduction of bacterial burden is expressed as log10
FPC counts  mean log10 FPC of the untreated
controls. Error bars indicate SEM. Results were
analyzed using a Student’s unpaired t test.
(C) Larvae 1 dpi with 300 far-red fluorescent Mm
and then treated with RIF (100 mM), TLM (400, 950,
or 1,900 mM), or both. Bacterial burdens were
measured by APF at 5 dpt. Bars represent
geometric mean RFU. Log10-transformed RFUs
were compared using ANOVA with a Dunnett’s
posttest. TLM-treated groups were compared to
their respective no-TLM controls (either with or
without RIF). ***p < 0.001.
(D) ROC analysis showing the predictive value of
the model to detect the activity of 400 mM TLM in
the presence of RIF (calculated from 100 mM-RIF-
only group versus 100 mMRIF/400 mMTLMgroup).without RIF to determine both the minimal effective concentra-
tion of TLM and the concentration at which it would synergize
with RIF (Figure 3C). We found that 1,900 mM TLM was required
when used alone, whereas in combination with a subtherapeutic
dose of RIF (100 mM), synergy was observed with as little as
400 mMTLM, our suggested screening concentration. ROC anal-
ysis yielded an AUC of 0.82 (p = 0.0001; Figure 3D). These results
suggest the feasibility of using APF to identify new compounds
that synergize with existing antitubercular agents.
APF Can Identify Host-Targeting Compounds and
Synergies between Host- and Bacterial-Targeting
Compounds
Next, we asked if APF could detect the indirect antitubercular
activity of host-targeting compounds. We have recently shown
that an increased susceptibility to mycobacterial infection is
associated with a hyperinflammatory state stemming from
overexpression of the leukotriene A4 hydrolase (lta4H) gene
(Tobin et al., 2010). The hyperinflammatory state permits
increased bacterial growth, which can be reduced by treat-
ment with anti-inflammatory compounds such as dexametha-
sone (DEX) and acetylsalicylic acid (ASA) (Tobin et al., 2012).
The APF assay detected the efficacy of both compounds to
reduce infection burdens in the context of the hyperinflamma-
tory state (Figure 4A). Another recent study showed that the
ABL tyrosine kinase family inhibitor imatinib (Gleevec) reduces
Mm and Mtb burdens in mice by targeting host pathways
(Napier et al., 2011). APF identified imatinib efficacy at concen-
trations as low as 10 mM (Figure 4B). Furthermore, we wereable to demonstrate that imatinib synergizes with traditional
antibacterial drugs: Combination treatment with 100 mM each
of imatinib and INH was more efficacious than either drug
alone (Figure 4C). Together, these results highlight the ability
of the APF platform to detect antitubercular activity of host-
targeting compounds and synergies with traditional antimicro-
bials, interactions that would not be detected in axenic culture
models.
DISCUSSION
We have developed and validated a comprehensive platform for
rapid, in vivo antitubercular drug discovery that combines
husbandry and transient, reversible anesthesia in 96-well plates,
with automated in situ assays for drug efficacy. These assays
monitor drug efficacy by two parameters—quantification of
bacterial burdens and host survival—within a compressed time
frame of 5 days. These are the key parameters by which antibi-
otic efficacy is assessed in mammalian models, usually over an
extended time frame of weeks to months. In addition, the auto-
mated microscopy platform provides more in-depth information
regarding the distribution and quality of infection, for example
whether or not granulomas form (Volkman et al., 2004). The fluo-
rimetry platform is faster and potentially more versatile, as it also
provides information on acute drug toxicity in the context of the
whole animal. However, the platform is not appropriate for the
study of long-term drug effects, either sterilization activity or
chronic toxicity. Compounds emerging from this platform still
need to be tested in adult animal models.Cell Reports 2, 175–184, July 26, 2012 ª2012 The Authors 179
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Figure 4. Host-Targeting Antimicrobials and Synergies
(A) WT and LTA4H-overexpressing larvae were infected with 300 far-red fluorescent Mm and then immediately treated for 2 days with 0.75 mMDEX or 1 mMASA.
*p < 0.05; **p < 0.01; ***p < 0.001.
(B and C) Larvae were infected with 300 far-red fluorescent Mm and then treated for 3 days. (B) Larvae were treated with various concentrations of imatinib, as
shown. (C) Larvae were treated with 100 mM imatinib, 100 mM INH, or a combination of both, as shown. For all panels, bars represent geometric mean RFUs. For
statistical analyses, data were log10-transformed and compared by one-way ANOVA with appropriate post hoc testing to accommodate multiple comparisons;
Bonferroni posttests for (A) and (C) and Dunnett’s posttest for (B). *p < 0.05; **p < 0.01; ***p < 0.001.Both of the platforms we describe would have quickly identi-
fied antitubercular agents in use today and are also sensitive
enough to detect drug synergies, even at subtherapeutic
concentrations of the individual agents. For example, our identi-
fication of a previously unrecognized drug synergism between
TLM and RIF was demonstrated in less than a week. The quest
for additional drugs that synergize with the current regimen
continues with the goal of further shortening treatment of drug-
susceptible TB. At the same time, it is important to identify
new synergistic regimens for drug-resistant TB. This larval plat-
form can serve both needs.
Utility for Discovery of In Vivo-Specific and Host-
Targeting Compounds
Mycobacteria, like other pathogens, express host-induced
determinants important for in vivo survival and virulence (McKin-
ney, 2000; Tobin and Ramakrishnan, 2008; Valdivia et al., 2000).
Indeed, the failure of in vitro target-based andwhole-cell screens
to identify compounds that are active in animal infection models
(Payne et al., 2007; Pethe et al., 2010) has highlighted the impor-
tance of developing screening platforms that better replicate
conditions in vivo. The development of HCS, which utilizes
bacteria grown in cultured cells, may partly address the short-
comings of older methods (Brodin and Christophe, 2011; Chris-
tophe et al., 2009). HCS methodologies, which also incorporate
toxicity screening, certainly provide higher throughput than the
larval platform described here. However, the larval platform
has some distinct advantages for primary screening as well.
While some mycobacterial determinants are activated upon
infection of macrophages in culture, others are only induced
upon granuloma formation in vivo (Davis et al., 2002; Ramak-
rishnan et al., 2000). Therefore, additional druggable targets
may be revealed only in the context of in vivo infection.
Furthermore, there is a growing appreciation that pathogenic
organisms induce and exploit host determinants for their own
benefit and that such factors can be targeted pharmacologically
to thwart infection (Agarwal et al., 2009; Chen et al., 2008; Kuijl180 Cell Reports 2, 175–184, July 26, 2012 ª2012 The Authorset al., 2007; Kumar et al., 2010; Schwegmann and Brombacher,
2008; Tobin et al., 2010, 2012; Volkman et al., 2010). For
example, mycobacteria require host kinases for intracellular
growth, inhibitors of which curb mycobacterial growth in
cultured macrophages, mice (Napier et al., 2011), and as we
now show, in zebrafish larvae. Likewise, mycobacteria are sensi-
tive to the fine balance of inflammatory responses, modification
of which can impact bacterial survival (Tobin et al., 2010, 2012).
These observations suggest the advantage of unbiased screens
in the context of in vivo infections. The utility of this approach is
highlighted by recent work in the zebrafish larva showing that
bacterial expansion ismediated in part by interactions of a bacte-
rial virulence determinant with the host matrix metalloproteinase
MMP9 (Volkman et al., 2010). As MMP9 is induced not in the in-
fectedmacrophages but in the surrounding epithelium, inhibitors
of this pathogen-beneficial pathway can only be identified in the
context of whole animals. The discovery of host-targeting antimi-
crobial compounds has the potential to improve treatment both
of drug-susceptible TB and drug-resistant disease. Thus, our
demonstration that the platform can identify host-targeting
compounds is an important validation of its unique potential.
The larval platform should also prove valuable in secondary
screening of lead compounds identified by a variety of other
methods. Use of the larvae to identify effective drugs and their
metabolic derivatives in the context of an active and intact phys-
iological system would reduce the number of leads subjected to
expensive in vivo toxicity and efficacy testing and would also
serve as a facile tool for lead optimization.
Practical Advantages
The platforms we describe further allow rapid and extensive
compound characterization in vivo using limited samples. For
example, evaluating the effect of INH treatment using five larvae
over the course of 10 days requires 69 mg of INH at the 400 mM
concentration used. In contrast, 25 mg would be required for
a similar assessment of compound efficacy in mice, assuming
a 25 mg/kg1/day1 dosing regimen (Stover et al., 2000).
Derivative compounds synthesized in small amounts for struc-
ture–activity relationships can also be rapidly characterized for
differences in their biological activity.
Another advantage of the larval model may be that pharmaco-
kinetic restrictions such as compound bioavailability are less
relevant, allowing for a primary assessment of pure biological
efficacy. For example, the efficacy of streptomycin can be
detected simply by soaking larvae in the drug (Adams et al.,
2011) but must be administered by injection in humans and
mice. The discovery of parent compounds without bioavailability
constraints in the zebrafish may then allow for their optimization
for human use. In this way, the larval platform represents the best
of both worlds—complex enough to identify drugs that can only
be identified in the context of in vivo infection but simple enough
to bypass bioavailability constraints.
Finally, the newer HCS methodologies require expensive and
computationally intensive microscopy (Brodin and Christophe,
2011), whereas the larval APF format delivers the same informa-
tion (efficacy and toxicity) more quickly and using more widely
available equipment. Given the failure of large pharmaceutical
companies to identify new antimicrobial drugs, and ready
access to drug libraries, drug discovery is increasingly shifting
to academic and nonprofit research groups and to smaller
biotechnology companies (Moellering, 2011). Thus, the larval
platform we describe may be accessible, although perhaps
with lower throughput, to a wider range of academic and
nonprofit research groups.
Algorithm for Drug Discovery
A combination of fluorimetric and microscopic techniques can
be used in the model to interface rapid drug screening with
detailed characterization of drug effects on disease pathogen-
esis (Figure S4). The screen should yield host-targeting com-
pounds as well as antibacterial compounds, the latter of which
may be selectively effective in vivo or also effective against
bacteria in culture. In this context, we note that many host-
targeting drugs, both in the context of TB and for other diseases,
have been found effective at concentrations <10 mM (Becker
et al., 2012; Cusick et al., 2012; Das et al., 2010; Laggner et al.,
2012; Ni et al., 2011; Tobin et al., 2010, 2012; White et al.,
2011). Therefore, it is possible that parallel screens with high
and low compound concentrations can be used to enrich for
bacterial and host-targeting drugs, respectively. As we have
detailed for INH, identification of a candidate drug by APF can
be rapidly followed by survival studies and/or low magnification
microscopy to determine EBA, dose-dependent efficacy and
tolerance. Synergy screens can be performed de novo to identify
combinations of compounds with increased EBA. Rapid evalua-
tion of drug toxicity is also feasible in this model (McGrath and
Li, 2008).
In summary, this work highlights the relevance, versatility, and
ease of the zebrafish larval platform for the discovery of
traditional antitubercular drugs and suggests its potential for
the discovery of entirely new types of anti-infectives. Zebrafish
are proving to be versatile models for infectious diseases and
are nowbeing used to study a variety of human pathogenswhere
drug resistance poses great difficulties. These include the
bacterial pathogens Burkholderia cenocepacia, Pseudomonasaeruginosa, Staphylococcus aureus, Streptococcus pyogenes,
and Francisella species; the fungal pathogen Candida albicans;
and the viral pathogen herpes simplex virus type 1 (Brannon
et al., 2009; Chao et al., 2010; Clatworthy et al., 2009; Prajsnar
et al., 2008; Szabady et al., 2009; Vergunst et al., 2010;
Wiles et al., 2009). The methods described here should be easily
extended for drug discovery efforts focused on these pathogens.
The use of these platforms is not limited to antibiotic screens;
indeed, they should be applicable to any screen involving fluores-
cence readouts in transgenic larvae. The use of green autofluor-
escence to detect larval death by fluorimetry should be useful for
screens of drug toxicity and toxin screens (Peterson andMacrae,
2012). Similarly, the temporary and reversible cryoanesthesia of
zebrafish larvae should be widely applicable for a variety of other
drug screens involving older, motile larvae with the obvious
exception of cardiac or motility-based drug screens.
EXPERIMENTAL PROCEDURES
Bacterial Strains and Methods
M. marinum strains M (ATCC BAA-535) and 4E4 (DkasB; Gao et al., 2003) ex-
pressed either GFPmut3 (plasmid pGFPHYG2; Cosma et al., 2006b), dsRed2
(plasmid pR2HYG, a hygromycin-resistant derivative of pMSP12::dsRed2;
Cosma et al., 2004), or tdKatushka2 (plasmid pTEC22, a derivative of
pGFPHYG2 in which the tdKatushka2 open reading frame [Axxora, San
Diego, CA] was used to replace gfpmut3). All plasmids are available from
AddGene. Bacteria were grown at 33C in Middlebrook 7H9 medium (Difco)
supplemented with 0.5% bovine serum albumin, 0.005% oleic acid, 0.2%
glucose, 0.2% glycerol, 0.085% sodium chloride, 0.05% Tween 80, and
50 mg/ml hygromycin. Single-cell suspensions of bacteria were prepared for
experimental infections as follows: 100 ml bacteria were grown to mid-log
phase, harvested by centrifugation, and resuspended in 1 ml medium. The
bacterial suspension was passed through a 27-gauge needle 10 times to
disrupt cell clumps and centrifuged at 1003 g, and the turbid supernatant
was collected in a clean tube. The pellet was again resuspended in 1 ml and
the process was repeated three times. The collected supernatants, which
consist of single cells and partially disrupted bacterial clumps, were then
passed through a sterile 5 mM filter. The resulting single-cell suspensions
were stored in 10 ml aliquots at 80C.
Zebrafish Infection, Husbandry, and Drug Treatment
Wild-type AB zebrafish were infected via caudal vein injections at 36–48 hr
postfertilization (Cosma et al., 2006a) with thawed single-cell suspensions.
Embryo maintenance and injection procedure were previously described
(Cosma et al., 2006a). LTA4H-overexpressing larvae were generated by injec-
tion of lta4h RNA into one-cell-stage embryos as previously described (Tobin
et al., 2012). Larvae were housed in optical bottom 96-well plates (Nunc
265301) containing a single larva per well in 250 ml filter-sterilized fish water
(Cosma et al., 2006a). Larval feeding was omitted, thus improving water quality
and avoiding the need to transfer larvae to fresh 96-well plates. Relying on the
yolk as their nutrient source, uninfected larvae survive up to 12 days dpf. All
drug treatment experiments were performed in fish water containing 1%
DMSO, except for DEX and ASA treatment experiments, which were per-
formed in 0.5% DMSO. All zebrafish husbandry and experiments were con-
ducted in accordance with the University of Washington Institutional Animal
Care and Use Committee regulations.
Microscopy
Wide-field microscopy was performed using a Nikon Eclipse Ti-E equipped
with a C-HGFIE 130W mercury light source and 23/0.10 Plan Apochromat
objective. Fluorescence images were captured with a CoolSNAP HQ2 Mono-
chrome Camera (Photometrics) using NIS-Elements (version 3.22). Fluores-
cence filter cubes sets included Chroma FITC (41001), TRITC (41002), and
ETmCherry (49008) for detection of green, red, and far-red light, respectively.Cell Reports 2, 175–184, July 26, 2012 ª2012 The Authors 181
Automatedmicroscopy was performed using the Nikon Ti-S-EMotor XY Stage
and custom macros programmed into AutoHotkey version 1.1 (Document S1:
Supplemental Software for High-Throughput Microscopy).
Fluorescent Pixel Count
Quantification of fluorescent Mm infection using images of individual embryos
has been described (Adams et al., 2011), and is detailed in Document S2:
Supplemental Software for Image Analysis.
Fluorimetry
Fluorimetry was performed using a Tecan GENios Pro microplate reader
equipped with 485/20 nm and 535/25 nm, 535/25 nm and 590/20 nm, or
595/10 nm and 650/10 nm filters for green, red, and far-red fluorescence
measurements, respectively. Bacterial fluorimetry readings were taken using
96-well black-bottom microplates (Costar 3915) loaded with single-cell bacte-
rial suspensions resuspended in 100 ml PBS. For APF, a 12-point 4 3 4 beam
pattern was used (see Document S3: APF Settings) to maximize the measured
surface area per well. Gain was optimized for individual experiments and
fluorescence intensity reported as relative fluorescence units (RFUs). For
experiments measuring infection burden via APF, the baseline fluorescence
of uninfected larvae was measured and subtracted from the fluorescence of
infected larvae.
Statistics
Statistical analyses were performed using Prism 5.01 (GraphPad). For data
sets requiring log10 transformation before analysis of variance (ANOVA),
embryos with no detectable fluorescence above background or with no
detectable CFU were assigned a value of 0.9, with 1 being the limit of
detection, before log10 transformation. Posttest p values are represented in
Figures 3 and 4 as follows: *p < 0.05; **p < 0.01; ***p < 0.001.
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